站在肿瘤免疫治疗的转折点上，NK细胞疗法展现出的不仅仅是技术突破，更是治疗范式的根本变革。从T细胞主导的精准打击，到NK细胞构建的多维防御，这种转变预示着个体化医疗向系统化治疗的进化。未来3-5年，随着基因编辑、微流控培养等技术的成熟，NK细胞疗法有望在实体瘤治疗领域实现50%的有效率突破。对于行业而言，建立跨学科研发平台、完善细胞制备质控体系、探索联合治疗新方案，将成为破局的关键三步棋。当免疫系 ...

为解决皮肤 T 细胞淋巴瘤（CTCL）治疗难题，研究人员探究 CD38 作用及联合疗法，发现联合治疗可提升疗效。 皮肤 T 细胞淋巴瘤（Cutaneous T-Cell Lymphoma，CTCL）是一种让人头疼的非霍奇金淋巴瘤，它专门 “攻击” 皮肤里的恶性 T 细胞。得了这种病，患者皮肤状况 ...

Natural killer (NK) cells are the human body’s first line of defense against cancer and infections but tend to get knocked down by treatment with anti-CD38 antibodies. This is because NK cells ...

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...

The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...

While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...